Desipramine

CHEMBL72 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
266.4 g/mol
LogP
4.9
Phase
4

A tricyclic antidepressant and active metabolite of imipramine that primarily inhibits norepinephrine reuptake, used for major depression, neuropathic pain, and sometimes ADHD. It has fewer anticholinergic and sedative effects than many other tricyclic antidepressants.

Masse moléculaire

266,4000 g/mol

LogP

4,90

TPSA

15,30 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Mécanisme d'action

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CNCCCN1c2ccccc2CCc2ccccc21

InChI

InChI=1S/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3

Molecular Formula

C18H22N2

HBD / HBA

1 / 2

Liaisons Rotatives

4

Atomes Lourds

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A tricyclic antidepressant and active metabolite of imipramine that primarily inhibits norepinephrine reuptake, used for major depression, neuropathic pain, and sometimes ADHD. It has fewer anticholinergic and sedative effects than many other tricyclic antidepressants.

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Yes, Desipramine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL72. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 2995. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.